Scanning electron micrograph of methicillin-resistant Staphylococcus aureus (MRSA) bacteria being engulfed by an immune cell known as a neutrophil. Johns Hopkins Medicine researchers have discovered that blocking a specific group of enzymes called caspases boosts the ability of immune cells, including neutrophils, to fight MRSA and other dangerous skin infections — and without the use of antibiotics.
Credit: National Institute of Allergy and Infectious Diseases, National Institutes of Health
Johns Hopkins Medicine study uncovers enzyme inhibitor that boosts immune system to fight MRSA and other dangerous skin infections
In what turned out to be one of the most important accidents of all time, Scottish bacteriologist Alexander Fleming returned to his laboratory after a vacation in 1928 to find a clear zone surrounding a piece of mold that had infiltrated a petri dish full of Staphylococcus aureus (S. aureus), a common skin bacterium he was growing.
That region of no bacterial growth was the unplanned birth of a medical miracle, penicillin, and would lead to the era of antibiotics. Now, in a paper published today in the journal Science Translational Medicine, researchers at Johns Hopkins Medicine have announced another accidentally discovered, potentially game-changing treatment — one that may provide an alternative immune-based solution to the danger of antibiotic-resistant bacterial infections.
And like Fleming’s surprise finding, the bacterium of note is once again S. aureus — but this time, methicillin-resistant Staphylococcus aureus, the life-threatening strain unharmed by methicillin and other antibiotics, and better known by its acronym, MRSA.
The paper’s senior author, Lloyd Miller, M.D., Ph.D., former professor of dermatology, infectious diseases and orthopaedic surgery at the Johns Hopkins University School of Medicine, and now with Janssen Research and Development, says the research team was originally intending to study the mechanisms behind MRSA skin infections in mice with and without the ability to manufacture interleukin-1 beta (IL-1?). This protein, transformed into its active form by enzymes called caspases, enhances protective immunity by helping immune cells called neutrophils, monocytes and macrophages fight bacterial infections.
“We gave the mice a blocker of all caspases [pancaspase inhibitor], a compound known as Q-VD-OPH, thinking it would leave both sets of mice more vulnerable to MRSA infection,” Miller says. “To our surprise, blocking caspases had the opposite effect, resulting in a rapid and remarkable clearing of the MRSA bacteria by keeping the immune cells alive and boosting their protective function.”
Sensing they might have accidentally uncovered a means of fighting bacterial “superbugs,” Miller and his colleagues conducted their latest study to confirm the unexpected finding was not a fluke.
The results were encouraging.
“A single oral dose of Q-VD-OPH decreased the size of MRSA skin lesions and rapidly cleared the bacteria compared with vehicle-treated [given the carrier solution without Q-VD-OPH] and untreated mice,” says study lead author Martin Alphonse, Ph.D., a dermatology postdoctoral fellow at the Johns Hopkins University School of Medicine. “And surprisingly, the treatment worked whether IL-1? was present or not — and without administering any antibiotics.”
The researchers, says Alphonse, found that the pancaspase inhibitor reduces apoptosis — one of three main methods the body uses to remove worn-out or damaged cells — of neutrophils and monocytes, leaving them in plentiful numbers and better able to remove MRSA bacteria.
“It’s like a fire department where older firetrucks are kept operating to help put out blazes, when otherwise, they would have been taken out of service,” says Miller.
The researchers also saw enhanced necroptosis — a second controlled cell death process similar to apoptosis — of macrophages, which are mature monocytes.
“The destruction of macrophages by necroptosis releases large amount of tumor necrosis factor, or TNF, a protein that triggers bacteria-fighting immune cells to swarm into an infected area of skin,” says Alphonse.
Finally, the researchers tested whether Q-VD-OPH in mice could have broader activity against two other dangerous skin bacteria, Streptococcus pyogenes (the cause of multiple diseases, including scarlet fever, necrotizing fasciitis and toxic shock syndrome) and Pseudomonas aeruginosa (often a threat to hospitalized patients on ventilators, with catheters or suffering wounds from surgery or burns). The targeting of the body’s immune system against bacteria via pancaspase inhibition — referred to as “host-directed immunotherapy” — proved just as successful as it had been for MRSA.
“It was an accidental finding by Alexander Fleming that led to the golden age of antibiotics, but now that’s nearing the end because of antibiotic-resistant bacteria,” says Miller. “It seems fitting that another surprise in the lab could be the start of a second golden age, the use of host-directed immunotherapy.”
More from: Johns Hopkins University School of Medicine
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
- Cue Biopharma, Inc. (CUE) CEO Dan Passeri on Q2 2021 Results - Earnings Call Transcripton August 17, 2021 at 6:40 pm
Q2 2021 Results Conference Call August 17, 2021 4:30 PM ET. Company Participants. Dr. George Zavoico - VP, IR & Corporate Development. Dan Passeri ...
- SELLAS Life Sciences Reports Second Quarter 2021 Financial Results and Provides Business Updateon August 12, 2021 at 1:27 pm
Reported Promising Updated Clinical Data in Ongoing Clinical Trials of Galinpepimut-S (GPS) in Combination with PD-1 Inhibitors for Malignant Pleural Mesothelioma (MPM) and WT1+ Advanced Ovarian ...
- Celsion Corporation Reports Second Quarter 2021 Financial Results and Provides Business Updateon August 12, 2021 at 5:00 am
Oncology and on Next-Generation Vaccine InitiativeConference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a ...
- IMV Inc. Announces Second Quarter 2021 Financial and Operational Resultson August 10, 2021 at 11:05 pm
IMV Inc. (the "Company" or "IMV") (TSX: IMV; NASDAQ: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies, today announced its financial and operational results ...
- Precigen, Inc. (PGEN) CEO Helen Sabzevari on Q2 2021 Results - Earnings Call Transcripton August 9, 2021 at 6:56 pm
Q2 2021 Results Earnings Conference Call August 09, 2021, 04:05 PM ET Company Participants Steven Harasym - Vice President, IR Helen Sabzevari - President ...
Go deeper with Google Headlines on:
Go deeper with Bing News on:
Antibiotic-resistant bacterial infections
- New sensor provides quick test to measure antibiotic resistanceon August 22, 2021 at 4:34 am
UBC Okanagan researchers have developed a method for monitoring bacterial responses to antibiotics in health-care settings that opens the door to personalized antibiotic therapy for patients.
- UC Merced: Antibiotic Resistance Found in Insecticides Commonly Used in Californiaon August 20, 2021 at 6:34 am
Because Bt colonizes in humans, it can make many kinds of bacterial infections drug resistant. “It is generally not considered a contributor to antibiotic resistance,” Sistrom said.
- Bacterial warfare provides new antibiotic targeton August 19, 2021 at 10:30 am
A detailed study of the weapons bacteria use to defeat their rivals has revealed a brand new target for antibiotics.
- Diagnostics Firm Readies for Pivotal FDA Study of Device That Detects Bacterial Lung Infectionson August 18, 2021 at 2:01 pm
Avisa Diagnostics Inc. (AVBT:CSE), a clinical-stage medical device company, aims to replace the standard of care for diagnosing and monitoring bacterial lung infections, ranging from tuberculosis and ...
- Antimicrobial Resistance ‘Arms Race’ Realizes Advancements as Post-Antibiotic Era Ensueson August 18, 2021 at 1:29 pm
Emerging innovations and non-antibiotic approaches to address urgent need to control infectious diseases, including multiple-drug resistant ‘super-bugs’ ...